Drug Trial Radar · NCT05174169
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,912
Planned (sponsor's estimate)
Start
Jul 8, 2022
Primary completion
Mar 10, 2029
Study completion Mar 10, 2030
Sponsor
- Lead sponsor
- NRG OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Natera, Inc.; National Cancer Institute (NCI)
- First posted
- Dec 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Conditions
- Stage III Colon Cancer
Interventions
Signatera testDevice
Central ctDNA testing for all patients
mFOLFOX6 3-6 monthDrug
Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles
CAPOX 3 monthDrug
Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
mFOLFIRINOXDrug
Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
mFOLFOX6 6 monthDrug
Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
CAPOX 6 monthDrug
Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- ctDNA positive status (TTPos)Time frame: Time from randomization to the first TTPos event, a maximum of 3 years
- Disease-Free Survival (DFS)Time frame: Time from randomization to disease-free survival event, a maximum of 5 years]
Locations
1,085 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Active not recruiting
Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
Daphne, Alabama · Suspended
Thomas Hospital
Fairhope, Alabama · Suspended
Mobile Infirmary Medical Center
Mobile, Alabama · Suspended
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama · Recruiting
Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
Saraland, Alabama · Suspended
Kingman Regional Medical Center
Kingman, Arizona · Recruiting
Cancer Center at Saint Joseph's
Phoenix, Arizona · Recruiting
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Active not recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Recruiting
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas · Suspended
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Kaiser Permanente-Anaheim
Anaheim, California · Recruiting
Kaiser Permanente-Deer Valley Medical Center
Antioch, California · Recruiting
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Recruiting
PCR Oncology
Arroyo Grande, California · Recruiting
Sutter Auburn Faith Hospital
Auburn, California · Recruiting
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California · Recruiting
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California · Recruiting
Kaiser Permanente-Baldwin Park
Baldwin Park, California · Recruiting
Kaiser Permanente-Bellflower
Bellflower, California · Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
Mills-Peninsula Medical Center
Burlingame, California · Recruiting
Marshall Cancer Center
Cameron Park, California · Recruiting
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California · Recruiting
Mercy Cancer Center - Carmichael
Carmichael, California · Recruiting
Mercy San Juan Medical Center
Carmichael, California · Recruiting
Eden Hospital Medical Center
Castro Valley, California · Recruiting
Enloe Medical Center
Chico, California · Recruiting
Sutter Davis Hospital
Davis, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Epic Care-Dublin
Dublin, California · Suspended
Kaiser Permanente Dublin
Dublin, California · Recruiting
Mercy Cancer Center - Elk Grove
Elk Grove, California · Recruiting
Epic Care Partners in Cancer Care
Emeryville, California · Suspended
Kaiser Permanente-Fontana
Fontana, California · Recruiting
Showing 40 of 1,085 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.